BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Pabla BS, Schwartz DA. Assessing Severity of Disease in Patients with Ulcerative Colitis. Gastroenterol Clin North Am 2020;49:671-88. [PMID: 33121688 DOI: 10.1016/j.gtc.2020.08.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
Number Citing Articles
1 Shahdadi Sardou H, Akhgari A, Mohammadpour AH, Beheshti Namdar A, Kamali H, Jafarian AH, Afrasiabi Garekani H, Sadeghi F. Optimization study of combined enteric and time-dependent polymethacrylates as a coating for colon targeted delivery of 5-ASA pellets in rats with ulcerative colitis. Eur J Pharm Sci 2021;168:106072. [PMID: 34774715 DOI: 10.1016/j.ejps.2021.106072] [Reference Citation Analysis]
2 Sinopoulou V, Gordon M, Limketkai BN, Mullin G, Aali G, Akobeng AK; Cochrane Gut Group. Prebiotics for induction of remission in ulcerative colitis. Cochrane Database of Systematic Reviews 2022;2022. [DOI: 10.1002/14651858.cd015084] [Reference Citation Analysis]
3 Ghoshal UC, Yadav A, Fatima B, Agrahari AP, Misra A. Small intestinal bacterial overgrowth in patients with inflammatory bowel disease: A case-control study. Indian J Gastroenterol 2021. [PMID: 34390471 DOI: 10.1007/s12664-021-01211-6] [Reference Citation Analysis]
4 Lin H, Bai Z, Wu Q, Chu G, Zhang Y, Guo X, Qi X. Inflammatory Indexes for Assessing the Severity and Disease Progression of Ulcerative Colitis: A Single-Center Retrospective Study. Front Public Health 2022;10:851295. [PMID: 35359771 DOI: 10.3389/fpubh.2022.851295] [Reference Citation Analysis]
5 M’koma AE. Inflammatory Bowel Disease: Clinical Diagnosis and Surgical Treatment-Overview. Medicina 2022;58:567. [DOI: 10.3390/medicina58050567] [Reference Citation Analysis]
6 Grgić D, Golubić K, Brinar M, Krznarić Ž. Predictive value of faecal calprotectin in ulcerative colitis - single centre experience. Ann Med 2022;54:1570-7. [PMID: 35635011 DOI: 10.1080/07853890.2022.2082518] [Reference Citation Analysis]
7 Choi D, Stewart AP, Bhat S. Ozanimod: A First-in-Class Sphingosine 1-Phosphate Receptor Modulator for the Treatment of Ulcerative Colitis. Ann Pharmacother 2021;:10600280211041907. [PMID: 34423657 DOI: 10.1177/10600280211041907] [Reference Citation Analysis]
8 Alhalabi M, Eddin KA, Cheha K, Abbas A. Subcutaneous golimumab induced and maintained clinical response in a child with a biological-experienced steroid-refractory flare of ulcerative colitis: A case report. Medicine (Baltimore) 2021;100:e27283. [PMID: 34559136 DOI: 10.1097/MD.0000000000027283] [Reference Citation Analysis]
9 Langley BO, Guedry SE, Goldenberg JZ, Hanes DA, Beardsley JA, Ryan JJ. Inflammatory Bowel Disease and Neutrophil-Lymphocyte Ratio: A Systematic Scoping Review. J Clin Med 2021;10:4219. [PMID: 34575330 DOI: 10.3390/jcm10184219] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Rotondo-Trivette S, Wang B, Luan Y, Fiehn O, Sun F, Michail S. Reduced fecal short-chain fatty acids in hispanic children with ulcerative colitis. Physiol Rep 2021;9:e14918. [PMID: 34278738 DOI: 10.14814/phy2.14918] [Reference Citation Analysis]